Skip to content

Total debt at other companies

Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$3.79M-16.8%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$395.09M+0.1%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$168.68M+623%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$2.68M-13.3%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$15.48M-9.4%
Biogen logo
BiogenBIIB

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$5.67B+85.5%

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Calculated from Scholar Rock’s reported figures.

Plus components not separately reported this period.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's total debt?
Scholar Rock (SRRK) reported total debt of $205.67M in Q1 2026.
How has Scholar Rock's total debt changed year-over-year?
Scholar Rock's total debt increased by 225.7% year-over-year, from $63.14M to $205.67M.
What is the long-term trend for Scholar Rock's total debt?
Over 5 years (2020 to 2025), Scholar Rock's total debt has grown at a 13.8% compound annual growth rate (CAGR), from $57.14M to $108.92M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.